PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC
Year: 2024
Type: article
Study design: Observational Study
Source: Anticancer Research
Authors: INSU KIM, SUN HA CHOI, SHIN YUP LEE, SEUNG SOO YOO, JI EUN PARK, KYEONG-CHEOL SHIN, JONG GEOL JANG, KYUNG SOO HONG, YONG SHIK KWON, SUN HYO PARK, KEUM-JU CHOI, CHI YOUNG JUNG, MI-HYUN KIM, SOO HAN KIM, HEE YUN SEOL, JEHUN KIM, JIN-HAN PARK, TAE HOON KIM, JUNG SEOP EOM, JUNE HONG AHN
Institutions: Dong-A University, Kyungpook National University, Inje University, Yeungnam University College, Yeungnam University, Keimyung University, Daegu Catholic University, Pusan National University Hospital, Pusan National University, Pusan National University Yangsan Hospital, Kosin University, Gyeongsang National University, Gyeongsang National University Changwon Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4402985475